Impact of pretreatment PET/MRI on radiooncologic target delineation in Hodgkin's lymphoma: a case series.

IF 2.5 3区医学 Q3 ONCOLOGY

Strahlentherapie und Onkologie Pub Date : 2025-08-14 DOI:10.1007/s00066-025-02446-4

Kai Kröger, Sebastian Lohmann, Michael Oertel, Peter Borchmann, Andrea Kerkhoff, Georg Lenz, Lars Stegger, Hans Theodor Eich

{"title":"Impact of pretreatment PET/MRI on radiooncologic target delineation in Hodgkin's lymphoma: a case series.","authors":"Kai Kröger, Sebastian Lohmann, Michael Oertel, Peter Borchmann, Andrea Kerkhoff, Georg Lenz, Lars Stegger, Hans Theodor Eich","doi":"10.1007/s00066-025-02446-4","DOIUrl":null,"url":null,"abstract":"Purpose: Positron-emission tomography combined with computed tomography (PET/CT) is the diagnostic standard for patients with Hodgkin's lymphoma. Positron-emission tomography combined with magnetic resonance imaging (PET/MRI) is an alternative diagnostic modality that reduces radiation exposure to the patient. This study aims to evaluate the potential merits of PET/MRI compared to PET/CT for target delineation for radiotherapy of Hodgkin's lymphoma.Methods: Five patients with newly diagnosed Hodgkin's lymphoma underwent PET/CT imaging directly followed by PET/MRI imaging as part of initial staging. Both modalities were subsequently compared regarding each patient's diagnosed involved nodal regions. Three of these patients received radiotherapy after the completion of chemotherapy. In the radiotherapy planning CT, different gross tumor volumes and clinical target volumes were contoured for both PET/CT and PET/MRI and quantitatively compared using the Dice coefficient.Results: No differences regarding the diagnosed disease stage were observed. The delineated tumor and target volumes showed minor differences without clinical significance.Conclusion: Positron-emission tomography/MRI is a viable option to assure adequate staging and later target delineation in patients with Hodgkin's lymphoma. Due to the reduction of radiation exposure compared to PET/CT, it might be the preferable option if readily available.","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Strahlentherapie und Onkologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00066-025-02446-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Positron-emission tomography combined with computed tomography (PET/CT) is the diagnostic standard for patients with Hodgkin's lymphoma. Positron-emission tomography combined with magnetic resonance imaging (PET/MRI) is an alternative diagnostic modality that reduces radiation exposure to the patient. This study aims to evaluate the potential merits of PET/MRI compared to PET/CT for target delineation for radiotherapy of Hodgkin's lymphoma.

Methods: Five patients with newly diagnosed Hodgkin's lymphoma underwent PET/CT imaging directly followed by PET/MRI imaging as part of initial staging. Both modalities were subsequently compared regarding each patient's diagnosed involved nodal regions. Three of these patients received radiotherapy after the completion of chemotherapy. In the radiotherapy planning CT, different gross tumor volumes and clinical target volumes were contoured for both PET/CT and PET/MRI and quantitatively compared using the Dice coefficient.

Results: No differences regarding the diagnosed disease stage were observed. The delineated tumor and target volumes showed minor differences without clinical significance.

Conclusion: Positron-emission tomography/MRI is a viable option to assure adequate staging and later target delineation in patients with Hodgkin's lymphoma. Due to the reduction of radiation exposure compared to PET/CT, it might be the preferable option if readily available.

查看原文本刊更多论文

预处理PET/MRI对霍奇金淋巴瘤放射肿瘤学靶标划定的影响：一个病例系列。

目的：正电子发射断层扫描联合计算机断层扫描（PET/CT）是霍奇金淋巴瘤的诊断标准。正电子发射断层扫描结合磁共振成像（PET/MRI）是一种减少患者辐射暴露的替代诊断方式。本研究旨在评估PET/MRI与PET/CT在霍奇金淋巴瘤放疗靶区划定方面的潜在优势。方法：5例新诊断的霍奇金淋巴瘤患者直接行PET/CT成像，然后进行PET/MRI成像作为初始分期的一部分。随后比较两种方式对每个患者的诊断累及淋巴结区域。其中3例患者化疗结束后接受放疗。在放疗计划CT中，分别对PET/CT和PET/MRI绘制不同的总肿瘤体积和临床靶体积，并使用Dice系数进行定量比较。结果：两组在诊断疾病分期上无差异。所描绘的肿瘤和靶体积差异不大，无临床意义。结论：正电子发射断层扫描/MRI是一种可行的选择，以确保霍奇金淋巴瘤患者的适当分期和后期靶点划定。由于与PET/CT相比，它减少了辐射暴露，如果容易获得，它可能是更好的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Strahlentherapie und Onkologie 医学-核医学

CiteScore

5.70

自引率

12.90%

发文量

141

审稿时长

3-8 weeks

期刊介绍： Strahlentherapie und Onkologie, published monthly, is a scientific journal that covers all aspects of oncology with focus on radiooncology, radiation biology and radiation physics. The articles are not only of interest to radiooncologists but to all physicians interested in oncology, to radiation biologists and radiation physicists. The journal publishes original articles, review articles and case studies that are peer-reviewed. It includes scientific short communications as well as a literature review with annotated articles that inform the reader on new developments in the various disciplines concerned and hence allow for a sound overview on the latest results in radiooncology research. Founded in 1912, Strahlentherapie und Onkologie is the oldest oncological journal in the world. Today, contributions are published in English and German. All articles have English summaries and legends. The journal is the official publication of several scientific radiooncological societies and publishes the relevant communications of these societies.